Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 220.5
(-3.08%)
TWD 220.5
(-3.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.33 Billion TWD | 6.83% |
| 2022 | 7.8 Billion TWD | 38.4% |
| 2021 | 5.64 Billion TWD | 22.7% |
| 2020 | 4.59 Billion TWD | 8.21% |
| 2019 | 4.24 Billion TWD | 35.3% |
| 2018 | 3.13 Billion TWD | 1.94% |
| 2017 | 3.07 Billion TWD | -7.46% |
| 2016 | 3.32 Billion TWD | 3.07% |
| 2015 | 3.22 Billion TWD | 179.6% |
| 2014 | 1.15 Billion TWD | 182.29% |
| 2013 | 409.08 Million TWD | 48.79% |
| 2012 | 274.93 Million TWD | -16.05% |
| 2011 | 327.49 Million TWD | -7.62% |
| 2010 | 354.52 Million TWD | -1.08% |
| 2009 | 358.39 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.3 Billion TWD | 100.38% |
| 2024 Q2 | 2.62 Billion TWD | 13.76% |
| 2023 Q4 | 1.14 Billion TWD | -56.58% |
| 2023 Q2 | 2.6 Billion TWD | -3.76% |
| 2023 Q3 | 2.64 Billion TWD | 1.61% |
| 2023 FY | 8.33 Billion TWD | 6.83% |
| 2023 Q1 | 2.7 Billion TWD | 93.51% |
| 2022 FY | 7.8 Billion TWD | 38.4% |
| 2022 Q3 | 3.65 Billion TWD | 165.12% |
| 2022 Q4 | 1.39 Billion TWD | -61.74% |
| 2022 Q1 | 1.37 Billion TWD | 4.62% |
| 2022 Q2 | 1.37 Billion TWD | 0.64% |
| 2021 Q3 | 1.38 Billion TWD | -4.42% |
| 2021 Q4 | 1.31 Billion TWD | -5.38% |
| 2021 FY | 5.64 Billion TWD | 22.7% |
| 2021 Q1 | 1.49 Billion TWD | 12.54% |
| 2021 Q2 | 1.44 Billion TWD | -3.22% |
| 2020 Q1 | 900.69 Million TWD | -23.29% |
| 2020 Q4 | 1.33 Billion TWD | 5.95% |
| 2020 Q2 | 1.07 Billion TWD | 19.56% |
| 2020 Q3 | 1.25 Billion TWD | 16.57% |
| 2020 FY | 4.59 Billion TWD | 8.21% |
| 2019 Q2 | 963.46 Million TWD | -10.72% |
| 2019 Q4 | 1.17 Billion TWD | 13.86% |
| 2019 FY | 4.24 Billion TWD | 35.3% |
| 2019 Q1 | 1.07 Billion TWD | 25.85% |
| 2019 Q3 | 1.03 Billion TWD | 7.03% |
| 2018 Q2 | 782.88 Million TWD | 14.58% |
| 2018 FY | 3.13 Billion TWD | 1.94% |
| 2018 Q4 | 857.41 Million TWD | 5.09% |
| 2018 Q3 | 815.89 Million TWD | 4.22% |
| 2018 Q1 | 683.28 Million TWD | -22.01% |
| 2017 Q2 | 747.79 Million TWD | 11.21% |
| 2017 FY | 3.07 Billion TWD | -7.46% |
| 2017 Q4 | 876.16 Million TWD | 11.85% |
| 2017 Q1 | 672.39 Million TWD | -15.39% |
| 2017 Q3 | 783.32 Million TWD | 4.75% |
| 2016 Q1 | 779.4 Million TWD | -8.33% |
| 2016 Q4 | 794.69 Million TWD | -1.52% |
| 2016 Q3 | 806.98 Million TWD | -14.78% |
| 2016 FY | 3.32 Billion TWD | 3.07% |
| 2016 Q2 | 946.95 Million TWD | 21.5% |
| 2015 FY | 3.22 Billion TWD | 179.6% |
| 2015 Q3 | 873.43 Million TWD | 14.89% |
| 2015 Q4 | 850.19 Million TWD | -2.66% |
| 2015 Q2 | 760.23 Million TWD | 2.05% |
| 2015 Q1 | 744.93 Million TWD | 129.68% |
| 2014 Q1 | 61.64 Million TWD | -51.52% |
| 2014 Q4 | 324.34 Million TWD | 19.03% |
| 2014 Q3 | 272.49 Million TWD | 284.45% |
| 2014 Q2 | 70.87 Million TWD | 14.99% |
| 2014 FY | 1.15 Billion TWD | 182.29% |
| 2013 Q1 | 108.63 Million TWD | 44.74% |
| 2013 Q4 | 127.14 Million TWD | 29.78% |
| 2013 Q3 | 97.97 Million TWD | 30.07% |
| 2013 Q2 | 75.32 Million TWD | -30.66% |
| 2013 FY | 409.08 Million TWD | 48.79% |
| 2012 FY | 274.93 Million TWD | -16.05% |
| 2012 Q1 | 45.88 Million TWD | -59.72% |
| 2012 Q2 | 52.01 Million TWD | 13.36% |
| 2012 Q3 | 101.69 Million TWD | 95.53% |
| 2012 Q4 | 75.05 Million TWD | -26.2% |
| 2011 Q1 | 76.23 Million TWD | -25.49% |
| 2011 Q2 | 69.58 Million TWD | -8.73% |
| 2011 Q3 | 67.76 Million TWD | -2.62% |
| 2011 Q4 | 113.91 Million TWD | 68.12% |
| 2011 FY | 327.49 Million TWD | -7.62% |
| 2010 Q3 | 89.57 Million TWD | -4.31% |
| 2010 Q2 | 93.6 Million TWD | 35.62% |
| 2010 Q1 | 69.02 Million TWD | 0.0% |
| 2010 Q4 | 102.32 Million TWD | 14.23% |
| 2010 FY | 354.52 Million TWD | -1.08% |
| 2009 FY | 358.39 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Grape King Bio Ltd | 8.53 Billion TWD | 2.279% |
| Standard Chem & Pharm CO., LTD. | 2.72 Billion TWD | -205.977% |
| Maywufa Company Ltd. | 854.37 Million TWD | -876.044% |
| ScinoPharm Taiwan, Ltd. | 1.21 Billion TWD | -585.783% |
| LIWANLI Innovation Co., Ltd. | 15.08 Million TWD | -55187.695% |
| YungShin Global Holding Corporation | 2.91 Billion TWD | -186.461% |
| PhytoHealth Corporation | 67.64 Million TWD | -12228.021% |
| SCI Pharmtech, Inc. | 350.32 Million TWD | -2280.387% |
| Formosa Laboratories, Inc. | 1.9 Billion TWD | -338.142% |
| PharmaEssentia Corporation | 4.49 Billion TWD | -85.515% |
| Bora Pharmaceuticals Co., LTD. | 6.99 Billion TWD | -19.278% |